{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:01:45Z","timestamp":1785013305051,"version":"3.55.0"},"reference-count":71,"publisher":"Begell House","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Oncog"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>CAR-T cells have shown efficacious in the treatment of hematologic malignancies; however, their efficacy towards solid tumors is so far limited by multiple challenges such as poor T cell infiltration, limited persistence, and immune suppression within the tumor tissue. On the other hand, tumor regression, especially of metastases, can spontaneously occur, which has long intrigued the scientific community. Spontaneous regression is thought to be associated with a more global immune response, triggered through the activation of both innate and adaptive immune cells. The viewpoint discusses strategies for combining CAR-T cell therapy with approaches stimulating innate immune responses to facilitate clearance of solid tumors. Currently explored approaches include vaccination, cytokine-driven activation, contact-dependent immune cell interactions, and pharmacological co-treatment, all aiming at reshaping the local environment through recruiting and activating innate immune cells together with CAR-T cells to form a more comprehensive anti-tumor response.<\/p>","DOI":"10.1615\/critrevoncog.2026063886","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:31:46Z","timestamp":1773675106000},"page":"23-33","source":"Crossref","is-referenced-by-count":0,"title":["Review Article: Does CAR-T Cell Therapy of Solid Cancer Need the Activation of an Innate Immune Response?"],"prefix":"10.1615","volume":"31","author":[{"given":"Markus","family":"Barden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Radha G, Lopus M. The spontaneous remission of cancer: Current insights and therapeutic significance. Transl Oncol. 2021;14(9):101166.","DOI":"10.1016\/j.tranon.2021.101166"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Cole WH, Everson TC. Spontaneous regression of cancer: Preliminary report. Ann Surg. 1956;144(3):366-\u0080\u009383.","DOI":"10.1097\/00000658-195609000-00007"},{"key":"3","doi-asserted-by":"crossref","unstructured":"L\u00fcke F, Harrer DC, Hahn J, Grube M, Pukrop T, Herr W, Reichle A, Heudobler D. Continuous complete remission in two patients with acute lymphoblastic leukemia and severe fungal infection following short-term, dose-reduced chemotherapy. Front Pharmacol. 2021;12:599552.","DOI":"10.3389\/fphar.2021.599552"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Mansour MK, Tam JM, Vyas JM. The cell biology of the innate immune response to Aspergillus fumigatus. Ann N Y Acad Sci. 2012;1273(1):78-\u0080\u009384.","DOI":"10.1111\/j.1749-6632.2012.06837.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Mitroulis I, Ruppova K, Wang B, Chen L-S, Grzybek M, Grinenko T, Eugster A, Troullinaki M, Palladini A, Kourtzelis I, Chatzigeorgiou A, Schlitzer A, Beyer M, Joosten LAB, Isermann B, Lesche M, Petzold A, Simons K, Henry I, Dahl A, Schultze JL, Wielockx B, Zamboni N, Mirtschink P, Coskun \u00dc\u009c, Hajishengallis G, Netea MG, Chavakis T. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell. 2018;172(1-2):147-\u0080\u0093161.e12.","DOI":"10.1016\/j.cell.2017.11.034"},{"key":"6","doi-asserted-by":"crossref","unstructured":"O'Neill LAJ, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. 2009;61(2):177-\u0080\u009397.","DOI":"10.1124\/pr.109.001073"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Rolf N, Kariminia A, Ivison S, Reid GS, Schultz KR. Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia. Eur J Immunol. 2015;45(7):1980-\u0080\u009390.","DOI":"10.1002\/eji.201444874"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hossain DMS, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J, Forman S, Bhatia R, Kuo Y-H, Kortylewski M. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123(1):15-\u0080\u009325.","DOI":"10.1182\/blood-2013-07-517987"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Jo S, Fotovati A, Duque-Afonso J, Cleary ML, van den Elzen P, Seif AE, Reid GSD. Differential depletion of bone marrow resident B-ALL after systemic administration of endosomal TLR agonists. Cancers. 2020;12(1).","DOI":"10.3390\/cancers12010169"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ronsley R, Kariminia A, Ng B, Mostafavi S, Reid G, Subrt P, Hijiya N, Schultz KR. The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. Pediatr Hematol Oncol. 2019;36(8):468-\u0080\u009381.","DOI":"10.1080\/08880018.2019.1667461"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Anupindi K, Malachowski J, Hodson I, Zhu D, June CH, Levine BL. The next innovations in chimeric antigen receptor T cell immunotherapies for cancer. Cytotherapy. 2025;27(7):795-\u0080\u0093811.","DOI":"10.1016\/j.jcyt.2025.05.010"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Abken H. CAR-T cell therapies in gastrointestinal cancers: Current clinical trials and strategies to overcome challenges. Nat Rev Gastroenterol Hepatol. 2025;22(7):463-\u0080\u009380.","DOI":"10.1038\/s41575-025-01062-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Lamplugh ZL, Wellhausen N, June CH, Fan Y. Microenvironmental regulation of solid tumour resistance to CAR-T cell therapy. Nat Rev Immunol. 2025:1-\u0080\u009319.","DOI":"10.1038\/s41577-025-01229-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Amit U, Uslu U, Verginadis II, Kim MM, Motlagh SAO, Diffenderfer ES, Assenmacher C-A, Bicher S, Atoche SJ, Ben-Josef E, Young RM, June CH, Koumenis C. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2024;121(31): e2403002121.","DOI":"10.1073\/pnas.2403002121"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Aznar MA, Good CR, Barber-Rotenberg JS, Agarwal S, Wilson W, Watts A, Zhang Z, Gonzales D, Donahue G, Hwang W-T, Rennels AK, Rech AJ, Kuramitsu S, Huang H, Glastad KM, Alexander KA, Plesa G, Dowd E, Brennan A, Siegel DL, Tanyi J, Haas A, Torigian DA, Nadolski G, Gonzalez VE, Hexner EO, Fraietta JA, Jadlowsky JK, Young RM, Berger SL, June CH, O\u0080\u0099'Hara MH. Clinical and molecular dissection of CAR-T cell resistance in pancreatic cancer. Cell Rep Med. 2025;6(9):102301.","DOI":"10.1016\/j.xcrm.2025.102301"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Barden M, Elsenbroich PR, Haas V, Ertelt M, Pervan P, Velas L, Gergely B, Sz\u00f6\u0151r \u00c1, Harrer DC, Bezler V, Holzinger A, Friis RUW, Vereb G, Sch\u00fctz GJ, Schoeder CT, Hombach AA, Abken H. Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function. J Immunother Cancer. 2024;12(12).","DOI":"10.1136\/jitc-2024-010208"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Harrer DC, Li S-S, Kaljanac M, Barden M, Pan H, Abken H. Fine-tuning the antigen sensitivity of CAR-T cells: Emerging strategies and current challenges. Front Immunol. 2023;14:1321596.","DOI":"10.3389\/fimmu.2023.1321596"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Uslu U, Castelli S, June CH. CAR-T cell combination therapies to treat cancer. Cancer Cell. 2024;42(8):1319-\u0080\u009325.","DOI":"10.1016\/j.ccell.2024.07.002"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Uslu U, June CH. Beyond the blood: Expanding CAR-T cell therapy to solid tumors. Nat Biotechnol. 2025;43(4):506-\u0080\u009315.","DOI":"10.1038\/s41587-024-02446-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Wellhausen N, Baek J, Gill SI, June CH. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. Nat Rev Cancer. 2024;24(9):614-\u0080\u009328.","DOI":"10.1038\/s41568-024-00723-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Pollard AJ, Bijker EM. A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol. 2021;21(2):83-\u0080\u0093100.","DOI":"10.1038\/s41577-020-00479-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Chen H, Gu Y, Song L, Si L. Next-generation vaccines against bacterial pathogens: mRNA and beyond. Front Immunol. 2025;16:1709794.","DOI":"10.3389\/fimmu.2025.1709794"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Mohamad Salleh H, Faruqu FN, Sinniah A, Wong P-F. Harnessing nanocarriers to advance vaccine development. BioDrugs. 2025:1-\u0080\u009322.","DOI":"10.1007\/s40259-025-00759-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Moon JH, Phoo MT, Kim Y, Ahn J, Kim A, Nam J, Lee S-H, Moon JJ, Son S. polysaccharide adjuvants as innate immune trainers: Bridging pattern recognition receptor (PRR) activation and metabolic reprogramming for synthetic vaccine design. Adv Sci. 2025:e09022.","DOI":"10.1002\/advs.202509022"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Ren K, Yu C, Yang Q, Zhang Q, Li P. Current status and potential of immune adjuvants in mycotoxin immune enhancement: Mechanisms, innovations, and applications. Adv Healthc Mater. 2025:e03644.","DOI":"10.1002\/adhm.202503644"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, W\u00f6ll S, Christ E, Weber D, Suchan M, Bukur T, Birtel M, Jahndel V, Mroz K, Hobohm K, Kranz L, Diken M, K\u00fchlcke K, T\u00fcreci \u00d6, Sahin U. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446-\u0080\u009353.","DOI":"10.1126\/science.aay5967"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Mackensen A, Haanen, John B A G, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, L\u00fcke F, Kutsch N, M\u00fcller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, K\u00fchlcke K, Preu\u00dfner L, Rengstl B, T\u00fcreci \u00d6\u0096, \u015eahin U. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844-\u0080\u009353.","DOI":"10.1038\/s41591-023-02612-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Brisse M, Ly H. Comparative structure and function analysis of the RIG-I-Like Receptors: RIG-I and MDA5. Front Immunol. 2019;10:1586.","DOI":"10.3389\/fimmu.2019.01586"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Verbeke R, Hogan MJ, Lor\u00e9 K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55(11):1993-\u0080\u00932005.","DOI":"10.1016\/j.immuni.2022.10.014"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Johnson LR, Lee DY, Eacret JS, Ye D, June CH, Minn AJ. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell. 2021;184(19):4981-\u0080\u009395.e14.","DOI":"10.1016\/j.cell.2021.08.004"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Hossain MA. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143(Pt 2):113365.","DOI":"10.1016\/j.intimp.2024.113365"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652-\u0080\u009369.","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Ouyang P, Wang L, Wu J, Tian Y, Chen C, Li D, Yao Z, Chen R, Xiang G, Gong J, Bao Z. Overcoming cold tumors: A combination strategy of immune checkpoint inhibitors. Front Immunol. 2024;15:1344272.","DOI":"10.3389\/fimmu.2024.1344272"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: From molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","DOI":"10.1038\/s41392-024-01979-x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S. Cold tumors: A therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.","DOI":"10.3389\/fimmu.2019.00168"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Birtel M, Voss R-H, Reinhard K, Rengstl B, Ouchan Y, Michel K, Hayduk N, Tillmann B, Becker R, Suchan M, Theobald M, Oehm P, T\u00fcreci \u00d6, Sahin U. A TCR-like CAR promotes sensitive antigen recognition and controlled T-cell expansion upon mRNA vaccination. Cancer Res Commun. 2022;2(8):827-\u0080\u009341.","DOI":"10.1158\/2767-9764.CRC-21-0154"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, M\u00fcller F, Rhee I, Yadav M, Dobrin A, Sadelain M, \u0141uksza M, Cohen N, Tang L, Basturk O, G\u00f6nen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, T\u00fcreci \u00d6\u0096, Greenbaum BD, Jarnagin WR, Drebin J, O'\u0080\u0099Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144-\u0080\u009350.","DOI":"10.1038\/s41586-023-06063-y"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, Pang N, Ohmoto A, Amisaki M, Zebboudj A, Odgerel Z, Bruno EM, Zhang SL, Cheng C, Elhanati Y, Derhovanessian E, Manning L, M\u00fcller F, Rhee I, Yadav M, Merghoub T, Wolchok JD, Basturk O, G\u00f6nen M, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Soares KC, Jarnagin WR, Drebin J, O'\u0080\u0099Reilly EM, Mellman I, Sahin U, T\u00fcreci \u00d6\u0096, Greenbaum BD, Balachandran VP. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature. 2025;639(8056):1042-\u0080\u009351.","DOI":"10.1038\/s41586-024-08508-4"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee J-H, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647(8089):488-\u0080\u009397.","DOI":"10.1016\/j.annonc.2025.09.066"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Hombach A, Barden M, Hannappel L, Chmielewski M, Rappl G, Sachinidis A, Abken H. IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Mol Ther. 2022;30(2):593-\u0080\u0093605.","DOI":"10.1016\/j.ymthe.2021.10.011"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Kagoya Y. Cytokine signaling in chimeric antigen receptor T-cell therapy. Int Immunol. 2024;36(2):49-\u0080\u009356.","DOI":"10.1093\/intimm\/dxad033"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Mac\u00eado NA, Brussolo NM, Haddad F, Fernandes TR, Andrade PV de, Orellana MD, Guerino-Cunha RL. Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 2022;13:947648.","DOI":"10.3389\/fimmu.2022.947648"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146-\u0080\u009362.","DOI":"10.1016\/j.ymthe.2023.09.021"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Thomas S, Abken H. CAR-T cell therapy becomes CHIC: \"\u0080\u009ccytokine help intensified CAR\" T cells. Front Immunol. 2022;13:1090959.","DOI":"10.3389\/fimmu.2022.1090959"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Abken H. CAR-T cells transform to trucks: Chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012;61(8):1269-\u0080\u009377.","DOI":"10.1007\/s00262-012-1202-z"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Abken H. TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145-\u0080\u00931154.","DOI":"10.1517\/14712598.2015.1046430"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Abken H. CAR-T cells releasing IL-18 Convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21(11):3205-\u0080\u009319.","DOI":"10.1016\/j.celrep.2017.11.063"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Dragon AC, Thoelke S, Mausberg P, Zimmermann K, Blasczyk R, Hudecek M, Abken H, Schambach A, Maecker-Kolhoff B, Eiz-Vesper B. LMP2A-targeting CAR-T cells equipped with inducible IL-18 to address EBV-associated malignancies. HLA. 2025;106(4):e70439.","DOI":"10.1111\/tan.70439"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, Kloth C, Stamopoulou A, Moritz T, Lode HN, Siebert N, Blasczyk R, Goudeva L, Schambach A, K\u00f6hl U, Eiz-Vesper B, Esser R. GMP-compliant manufacturing of TRUCKs: CAR-T cells targeting GD(2) and releasing inducible IL-18. Front Immunol. 2022;13:839783.","DOI":"10.3389\/fimmu.2022.839783"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Harrer DC, Schenkel C, Bezler V, Kaljanac M, Hartley J, Barden M, Pan H, Holzinger A, Herr W, Abken H. CAR-triggered release of Type-1 Interferon limits CAR-T-cell activities by an artificial negative autocrine loop. Cells. 2022;11(23).","DOI":"10.3390\/cells11233839"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866.","DOI":"10.3389\/fimmu.2022.844866"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697-\u0080\u0093706.","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Lanzar ZR, Aldridge DL, Jayaraman B, Haskins B, Howard CA, Arana K, Bunkofske ME, Mulka K, Pardy RD, Byerly J, Striepen B, Lupardus P, Hunter CA. De-coupling immune parameters and toxicity associated with IL-12 agonism. Cell Rep. 2025;44(6):115840.","DOI":"10.1016\/j.celrep.2025.115840"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. IL-18-secreting CAR-T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133(9).","DOI":"10.1172\/JCI166028"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang W-T, Hexner E, Schuster SJ, June CH. Enhanced CAR-T-cell therapy for lymphoma after previous failure. N Engl J Med. 2025;392(18): 1824-\u0080\u009335.","DOI":"10.1056\/NEJMoa2408771"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, V\u00f6lkl S, Hartley J, Dreger C, Petry K, Bosio A, D\u00f6llen A von, Hartmann W, Lode H, G\u00f6rlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Preclinical development of CAR-T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clin Cancer Res. 2024;30(16):3564-\u0080\u009377.","DOI":"10.1158\/1078-0432.CCR-23-3157"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Zuo Y, Vohwinkel DJ, Dong B, McDowell JR, Guzman BV, Pandian TS, Chattopadhyay S, McGray AJ, Olejniczak SH, Ohm J, Wang J. IL-36\u03b3 armored CAR-T cells reprogram neutrophils to induce endogenous antitumor immunity. Cancer Cell. 2026;44(2):366-\u0080\u009382.","DOI":"10.1016\/j.ccell.2025.11.007"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Li X, Daniyan AF, Lopez AV, Purdon TJ, Brentjens RJ. Cytokine IL-36\u03b3 improves CAR-T-cell functionality and induces endogenous antitumor response. Leukemia. 2021;35(2):506-\u0080\u009321.","DOI":"10.1038\/s41375-020-0874-1"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Carcopino C, Erdogan E, Henrich M, Kobold S. Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. Immuno-Oncol Technol. 2024;24:100739.","DOI":"10.1016\/j.iotech.2024.100739"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Kwon N, Chen YY. Overcoming solid-tumor barriers: Armored CAR-T cell therapy. Trends Cancer. 2025;11(10):1019-\u0080\u009329.","DOI":"10.1016\/j.trecan.2025.08.009"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Zugasti I, Espinosa-Aroca, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, Urbano-Ispizua \u00c1, Esteve J, Velasco-Hernandez T, Men\u00e9ndez P. CAR-T cell therapy for cancer: Current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","DOI":"10.1038\/s41392-025-02269-w"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23(4):769-\u0080\u009378.","DOI":"10.1038\/mt.2015.4"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Kuhn NF, Lopez AV, Li X, Cai W, Daniyan AF, Brentjens RJ. CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR-T cell antitumor function. Nat Commun. 2020;11(1):6171.","DOI":"10.1038\/s41467-020-19833-3"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35(3):473-\u0080\u009388.e6.","DOI":"10.1016\/j.ccell.2019.02.006"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Blokon-Kogan D, Levi-Mann M, Malka-Levy L, Itzhaki O, Besser MJ, Shiftan Y, Sz\u00f6\u0151r \u00c1, Vereb G, Gross G, Abken H, Weinstein-Marom H. Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy. J Immunother Cancer. 2022;10(9): e001544.","DOI":"10.1136\/jitc-2020-001544"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Harrer DC, D\u00f6rrie J, Schaft N. CARs and drugs: Pharmacological ways of boosting CAR-T-cell therapy. Int J Mol Sci. 2023;24(3).","DOI":"10.3390\/ijms24032342"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Chen S, Saeed, Abdullah F U H, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","DOI":"10.1038\/s41392-023-01452-1"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Nerdinger YG, Binder AK, Bremm F, Feuchter N, Schaft N, D\u00f6rrie J. STINGing cancer: Development, clinical application, and targeted delivery of STING agonists. Int J Mol Sci. 2025;26(18).","DOI":"10.3390\/ijms26189008"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Uslu U, Sun L, Castelli S, Finck AV, Assenmacher C-A, Young RM, Chen ZJ, June CH. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. Nat Commun. 2024;15(1):3933.","DOI":"10.1038\/s41467-024-47692-9"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Jacoby J, Mahalingam D, Alistar A, Garmey E, Kazmi S, Mooneyham T, Sun L, Yap TA, Vu P, Moser J. Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies. J Immunother Cancer. 2025;13(6).","DOI":"10.1136\/jitc-2025-011572"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Kuhl N, Linder A, Philipp N, Nixdorf D, Fischer H, Veth S, Kuut G, Xu TT, Theurich S, Carell T, Subklewe M, Hornung V. STING agonism turns human T cells into interferon-producing cells but impedes their functionality. EMBO Rep. 2023;24(3):e55536.","DOI":"10.15252\/embr.202255536"}],"container-title":["Critical Reviews\u2122 in Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/66ce53f15d229f0e\/CRO-63886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:34:30Z","timestamp":1785011670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/439f422d0783386a,5a518e4904bba712,66ce53f15d229f0e.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevoncog.2026063886","relation":{},"ISSN":["0893-9675"],"issn-type":[{"value":"0893-9675","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}